AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14518728 — intervention group
Group type: EXPERIMENTAL
Intervention: Feature extraction module calculating average gray level and 48 texture characteristics.
Number of subjects: 0
Study 14518728 — intervention group
Group type: EXPERIMENTAL
Intervention: Three sequentially placed feed-forward neural networks (NNs) for classification.
Number of subjects: 0
Study 10648311 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (S)
Number of subjects: 51
Study 10648311 — intervention group
Group type: COMPARATOR
Intervention: Halothane (H)
Number of subjects: 51
Study 8712329 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine 2.5 micrograms.kg‐1
Number of subjects: 75
Study 8712329 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine 5 micrograms.kg‐1
Number of subjects: 75
Study 8712329 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 75
Study 1947865 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Care (CC)
Number of subjects: 16
Study 1947865 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 16
Study 1947865 — intervention group
Group type: COMPARATOR
Intervention: Non-schizophrenic patients
Number of subjects: 16
Study 1947865 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenic patients
Number of subjects: 16
Study 6387563 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon
Number of subjects: 40
Study 6387563 — intervention group
Group type: COMPARATOR
Intervention: Air/BSS (Control)
Number of subjects: 40
Study 29300100 — intervention group
Group type: EXPERIMENTAL
Intervention: UC + CALM ARC (7-session, group-based, computer-assisted but therapist-directed treatment)
Number of subjects: 97
Study 29300100 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 97
Study 28416391 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-plane ultrasound guidance (Group I, n = 43)
Number of subjects: 86
Study 28416391 — intervention group
Group type: COMPARATOR
Intervention: In-plane ultrasound guidance (Group II, n = 43)
Number of subjects: 86
Study 25917860 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated lidocaine/tetracaine patch
Number of subjects: 0
Study 25917860 — intervention group
Group type: COMPARATOR
Intervention: Subacromial corticosteroid injection
Number of subjects: 0
Study 24169242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 221
Study 24169242 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 221
Study 21915866 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN alfa‐2b for 52 weeks
Number of subjects: 303
Study 21915866 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 48 weeks
Number of subjects: 303
Study 18249219 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in moderate-to-vigorous physical activity (PA)
Number of subjects: 487
Study 18249219 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in total and moderate-to-vigorous physical activity (PA)
Number of subjects: 487
Study 18249219 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in total physical activity (PA)
Number of subjects: 487
Study 16801300 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinized cigarette
Number of subjects: 11
Study 16801300 — intervention group
Group type: COMPARATOR
Intervention: Denicotinized cigarette
Number of subjects: 11
Study 12765960 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Glucose Tolerance (NGT)
Number of subjects: 815
Study 12765960 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired Fasting Glucose (IFG) - Impaired Glucose Tolerance (IGT)
Number of subjects: 815
Study 12765960 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal FPG
Number of subjects: 815
Study 12765960 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired FPG or 2hPG
Number of subjects: 815
Study 11128360 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg ramipril
Number of subjects: 140
Study 11128360 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg ramipril
Number of subjects: 140
Study 11128360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 11128360 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ramipril treatment
Number of subjects: 140
Study 11128360 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (both doses)
Number of subjects: 140
Study 8775534 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril therapy
Number of subjects: 0
Study 1427244 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management education program
Number of subjects: 324
Study 1427244 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 324
Study 6374533 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 150 mg intramuscular dose of netilmicin
Number of subjects: 42
Study 6374533 — intervention group
Group type: COMPARATOR
Intervention: Five-day course of oral co-trimoxazole
Number of subjects: 42
Study 30707598 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition-related practices reported by providers
Number of subjects: 166
Study 30707598 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic providers' feeding practices
Number of subjects: 166
Study 30707598 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic providers' unhealthy food practices
Number of subjects: 166
Study 30707598 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic providers' screen usage during meals
Number of subjects: 166
Study 30707598 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic providers' nutrition training
Number of subjects: 166
Study 30707598 — intervention group
Group type: EXPERIMENTAL
Intervention: NAP SACC practices met by providers
Number of subjects: 166
Study 30707598 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnic differences in meeting NAP SACC guidelines
Number of subjects: 166
Study 29634843 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffractive trifocal IOL (AT LISA tri 839MP; Carl Zeiss Meditec)
Number of subjects: 55
Study 29634843 — intervention group
Group type: COMPARATOR
Intervention: Diffractive bifocal IOL (AT LISA 809M; Carl Zeiss Meditec)
Number of subjects: 55
Study 27002181 — intervention group
Group type: EXPERIMENTAL
Intervention: NS3623 (dual K(+) current activator)
Number of subjects: 0
Study 24318410 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous absorbable intradermal sutures
Number of subjects: 193
Study 24318410 — intervention group
Group type: COMPARATOR
Intervention: Interrupted nonabsorbable sutures
Number of subjects: 193
Study 22908698 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified flour with seven vitamins and minerals
Number of subjects: 300
Study 22908698 — intervention group
Group type: COMPARATOR
Intervention: Unfortified flour
Number of subjects: 300
Study 20207695 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulization with hypertonic saline 30 min before gastric lavage (n = 36)
Number of subjects: 104
Study 20207695 — intervention group
Group type: COMPARATOR
Intervention: Gastric lavage without prior nebulization (n = 68)
Number of subjects: 104
Study 17439600 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornstarch-thickened formula (group A)
Number of subjects: 81
Study 17439600 — intervention group
Group type: COMPARATOR
Intervention: 25% strengthened regular formula (group B)
Number of subjects: 81
Study 16355647 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised tooth-brushing with 1.23% APF gel (1 minute once a week)
Number of subjects: 258
Study 16355647 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised tooth-brushing with placebo
Number of subjects: 258
Study 16355647 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 258
Study 12386505 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery catheter (PAC) led therapy
Number of subjects: 0
Study 12386505 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 9474450 — intervention group
Group type: EXPERIMENTAL
Intervention: Crazy lens
Number of subjects: 9
Study 9474450 — intervention group
Group type: COMPARATOR
Intervention: Clear lens
Number of subjects: 9
Study 7656962 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype small-volume steel holding chamber
Number of subjects: 164
Study 7656962 — intervention group
Group type: COMPARATOR
Intervention: Large-volume, single-valved plastic Nebuhaler
Number of subjects: 164
Study 2666640 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT, Retrovir)
Number of subjects: 70
Study 2666640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 201440 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg fluoride as NaF in a watery solution
Number of subjects: 6
Study 201440 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg fluoride in tablet form (D‐Fluoretten 1000)
Number of subjects: 6
Study 201440 — intervention group
Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 6
Study 31146772 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (n = 42)
Number of subjects: 84
Study 31146772 — intervention group
Group type: COMPARATOR
Intervention: Sham control (n = 42)
Number of subjects: 84
Study 28032641 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tumor shrinkage (ETS) observed in first-line treatment
Number of subjects: 0
Study 28032641 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor early tumor shrinkage (mETS)
Number of subjects: 0
Study 28032641 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor progression (mPD)
Number of subjects: 0
Study 28032641 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression (PD)
Number of subjects: 0
Study 28032641 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tumor shrinkage (ETS) in second-line therapy
Number of subjects: 0
Study 28032641 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor early tumor shrinkage (mETS) in second-line therapy
Number of subjects: 0
Study 28032641 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor progression (mPD) in second-line therapy
Number of subjects: 0
Study 28032641 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression (PD) in second-line therapy
Number of subjects: 0
Study 26444022 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 36
Study 23660094 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosine within 6 hours (600 mg twice a day for 10-14 days)
Number of subjects: 85
Study 23660094 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosine after 6 hours (600 mg twice a day for 10-14 days)
Number of subjects: 85
Study 23660094 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy group (routine treatments)
Number of subjects: 85
Study 23660094 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including inosine and control)
Number of subjects: 85
Study 21500884 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissonance-based prevention program
Number of subjects: 306
Study 21500884 — intervention group
Group type: COMPARATOR
Intervention: Educational brochure control condition
Number of subjects: 306
Study 19515754 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Parent Education Program (COPE)
Number of subjects: 0
Study 19515754 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 0
Study 19515754 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical intervention group
Number of subjects: 0
Study 17350370 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg twice daily
Number of subjects: 64
Study 17350370 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 64
Study 15611205 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program for chronic illness
Number of subjects: 0
Study 11779601 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous beta-thalassemia patients
Number of subjects: 130
Study 11779601 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 130
Study 9667227 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (MEL) 12 mg orally
Number of subjects: 7
Study 9667227 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine 60 mg orally
Number of subjects: 7
Study 9667227 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MEL and pyridostigmine
Number of subjects: 7
Study 9667227 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (1.2 mg bolus followed by i.v. infusion of 1.6 mg/h for 3 hours)
Number of subjects: 7
Study 9667227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 8134442 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy at 2.5 atmospheres for 90 minutes, 5 days per week for 30 treatments
Number of subjects: 16
Study 8134442 — intervention group
Group type: COMPARATOR
Intervention: Air therapy at 2.5 atmospheres for 90 minutes, 5 days per week for 30 treatments
Number of subjects: 16
Study 2510265 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil, 300 micrograms b.d.
Number of subjects: 194
Study 2510265 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine, 150 mg b.d.
Number of subjects: 194
Study 4560728 — intervention group
Group type: EXPERIMENTAL
Intervention: Benorylate
Number of subjects: 15
Study 4560728 — intervention group
Group type: COMPARATOR
Intervention: Soluble aspirin
Number of subjects: 15
Study 30239456 — intervention group
Group type: EXPERIMENTAL
Intervention: Exponential tapering (n = 79)
Number of subjects: 158
Study 30239456 — intervention group
Group type: COMPARATOR
Intervention: Linear tapering (n = 79)
Number of subjects: 158
Study 30796456 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD implantation
Number of subjects: 1116
Study 30796456 — intervention group
Group type: COMPARATOR
Intervention: Control (usual clinical care)
Number of subjects: 1116
Study 28905498 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimagrumab 30 mg/kg i.v.
Number of subjects: 24
Study 28905498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 26369371 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal surgery
Number of subjects: 183
Study 26369371 — intervention group
Group type: COMPARATOR
Intervention: Postnatal repair
Number of subjects: 183
Study 23506744 — intervention group
Group type: EXPERIMENTAL
Intervention: Dignity therapy (DT) + standard palliative care (SPC)
Number of subjects: 60
Study 23506744 — intervention group
Group type: COMPARATOR
Intervention: Standard palliative care (SPC) alone
Number of subjects: 60
Study 21725053 — intervention group
Group type: EXPERIMENTAL
Intervention: WRAPID pharmacogenetics-guided initiation protocol
Number of subjects: 167
Study 19837300 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of recombinant human erythropoietin (rHuEPO) at 150 IU/kg, 4 doses at 48-hour intervals
Number of subjects: 16
Study 19837300 — intervention group
Group type: COMPARATOR
Intervention: Control group received 0.5 mL/kg isotonic solution
Number of subjects: 16
Study 16376081 — intervention group
Group type: EXPERIMENTAL
Intervention: 27 gauge needle
Number of subjects: 90
Study 16376081 — intervention group
Group type: COMPARATOR
Intervention: 23 gauge needle
Number of subjects: 90
Study 12753365 — intervention group
Group type: EXPERIMENTAL
Intervention: rPrtC of Porphyromonas gingivalis
Number of subjects: 34
Study 12638099 — intervention group
Group type: EXPERIMENTAL
Intervention: Heatwrap therapy
Number of subjects: 219
Study 12638099 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 219
Study 9607135 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous procainamide (1 g over 30 minutes, followed by an infusion of 2 mg/min over 1 hour)
Number of subjects: 114
Study 9607135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 8553118 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexion exercise and posture
Number of subjects: 149
Study 8553118 — intervention group
Group type: EXPERIMENTAL
Intervention: Extension exercise and posture
Number of subjects: 149
Study 8553118 — intervention group
Group type: COMPARATOR
Intervention: No exercise or posture (Control)
Number of subjects: 149
Study 2243887 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pilocarpine (25 mg)
Number of subjects: 13
Study 2243887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 354047 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxamniquine (Vansil) at an oral dose of 15 mg/kg twice a day for 2 days (total dose 60 mg/kg)
Number of subjects: 0
Study 354047 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxamniquine (Vansil)
Number of subjects: 0
Study 30876430 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical dropper (group M)
Number of subjects: 200
Study 30876430 — intervention group
Group type: COMPARATOR
Intervention: T-connector (group C)
Number of subjects: 200
Study 30876430 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study 28150516 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegLira (fixed-ratio combination of insulin degludec and liraglutide)
Number of subjects: 0
Study 28150516 — intervention group
Group type: COMPARATOR
Intervention: Alternative insulin regimens
Number of subjects: 0
Study 26012938 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic knee and postural stabilization exercises (Group 1, n=22)
Number of subjects: 42
Study 26012938 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic knee exercises only (Group 2, n=20)
Number of subjects: 42
Study 23503652 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxyvitamin D3 (1,25D)
Number of subjects: 45
Study 23503652 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfection of pre-miR-100 and pre-miR-125b with 1,25D
Number of subjects: 45
Study 23503652 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfection of pre-miR-100 and pre-miR-125b
Number of subjects: 45
Study 23503652 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-miR-125b transfection
Number of subjects: 45
Study 23503652 — intervention group
Group type: EXPERIMENTAL
Intervention: Knockdown of miR-125b in normal cells
Number of subjects: 45
Study 23503652 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25D
Number of subjects: 45
Study 21562841 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing TKA
Number of subjects: 33
Study 21562841 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing TKA
Number of subjects: 33
Study 19500615 — intervention group
Group type: EXPERIMENTAL
Intervention: Target preview (specific condition)
Number of subjects: 0
Study 19500615 — intervention group
Group type: COMPARATOR
Intervention: Categorical condition (without target preview)
Number of subjects: 0
Study 16402278 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel alone (175 mg/m2/IV)
Number of subjects: 10
Study 16402278 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel with Tamoxifen (TAM) (160 mg/m2 PO BID on Days 1-5 followed by paclitaxel 175 mg/m2/IV on Day 5)
Number of subjects: 10
Study 15306531 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg (n = 12)
Number of subjects: 22
Study 15306531 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 22
Study 11673304 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereophotographs using a stereoviewer
Number of subjects: 150
Study 11673304 — intervention group
Group type: COMPARATOR
Intervention: Single image from the same stereopair (monoscopic)
Number of subjects: 150
Study 11673304 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereoscopic imaging (interobserver)
Number of subjects: 150
Study 11673304 — intervention group
Group type: COMPARATOR
Intervention: Monoscopic imaging (interobserver)
Number of subjects: 150
Study 9408613 — intervention group
Group type: COMPARATOR
Intervention: High-osmolar contrast
Number of subjects: 111
Study 9408613 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-osmolar contrast
Number of subjects: 111
Study 8353089 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg three times a day for 15 days
Number of subjects: 82
Study 8353089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 29923950 — intervention group
Group type: EXPERIMENTAL
Intervention: Costoclavicular approach (Gp-CC)
Number of subjects: 40
Study 29923950 — intervention group
Group type: COMPARATOR
Intervention: Lateral sagittal approach (Gp-LS)
Number of subjects: 40
Study 27543595 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized daptomycin dosing protocol
Number of subjects: 0
Study 27543595 — intervention group
Group type: COMPARATOR
Intervention: Preimplementation group (control)
Number of subjects: 0
Study 25231685 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive pharmacologic cancer pain therapy (CPT)
Number of subjects: 52
Study 25231685 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CPT)
Number of subjects: 52
Study 22321082 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating Laryngeal Mask Airway™ (ILMA)
Number of subjects: 80
Study 22321082 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal Mask Airway CTrach™ (LMA CTrach)
Number of subjects: 80
Study 20600025 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) monotherapy
Number of subjects: 105
Study 20600025 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) combination therapy
Number of subjects: 105
Study 20600025 — intervention group
Group type: COMPARATOR
Intervention: TDF monotherapy
Number of subjects: 105
Study 20600025 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (FTC/TDF)
Number of subjects: 105
Study 18513662 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Care (skin contact) for 30 minutes before heel stick
Number of subjects: 10
Study 18513662 — intervention group
Group type: COMPARATOR
Intervention: Incubator care (inclined, nested and prone)
Number of subjects: 10
Study 16162447 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 0
Study 12736834 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimmers
Number of subjects: 20
Study 12736834 — intervention group
Group type: COMPARATOR
Intervention: Runners
Number of subjects: 20
Study 10368942 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable-time schedule
Number of subjects: 15